Mumbai : Sun Pharmaceutical Industries Ltd announced that several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, will be presented at the 2017 Annual American Academy of Dermatology (AAD) Meeting taking place March 3-7 in Orlando, Florida.
“Not all people with psoriasis respond to currently available therapies or are able to maintain long-term symptom control. We are looking forward to sharing new and continued insights about tildrakizumab at AAD and upcoming meetings,” said Jesper Jensen, Executive Vice President, Biologics and Dermatology, Sun Pharma. “With origins in dermatology that stretch back more than 30 years, we are committed to patients suffering from skin conditions. At Sun Dermatology, we care to make a difference.”
Tildrakizumab data analyses being presented at AAD include:
Tildrakizumab, a Selective Anti-IL-23 Monoclonal Antibody, Is Effective in Subjects With Chronic Plaque Psoriasis Who Do Not Adequately Respond to Etanercept – Poster 5252 (Pearls of the Symposium Session on Friday, March 3rd from 2:30 PM to 2:40 PM)
Efficacy of Tildrakizumab, an Anti-IL23p19 Monoclonal Antibody, Stratified by Prior Exposure to Biologics in a Randomized, Placebo-Controlled Phase 3 Clinical Trial – Poster 5111 (Psoriasis & Other Papulosquamous Disorders Section on Sunday, March 5th from 9:20 AM to 9:25 AM)
Maintenance of Treatment Response in Chronic Plaque Psoriasis Patients Continuing Treatment or Discontinuing Treatment With Tildrakizumab in a 64-Week, Randomized Controlled, Phase 3 Trial Poster 4855 (Psoriasis & Other Papulosquamous Disorders Section onSunday, March 5th from 11:35 AM to 11:40 AM)
The Effect of Tildrakizumab, a High-Affinity, Selective Anti-IL23p19 Monoclonal Antibody, on Cytochrome P450 Metabolism – Poster 4792 (Pharmacology Section on Sunday, March 5th from 12:55 PM to 1:00 PM)
Over 1,800 patients across more than 200 clinical sites participated in the tildrakizumab Phase-3 pivotal trials (reSURFACE 1 and 2). Data were presented for the first time demonstrating results through 28 weeks of treatment at the European Academy of Dermatology and Venerology (EADV) Congress in October 2016. Regulatory filings for tildrakizumab in the U.S. and Europe are proceeding as planned.
Source: Press Release
0 comment(s) on Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting
Dear user, we've recently made some changes in our website to make it more secure & accessible. We request you to Reset your password in case you get any problem in logging in your account. For any help, contact on +91 11 43720751 or Email on email@example.com
Please activate your account
Please click on the "account activation link" we have sent to your registered email.